# Josep Carreras Leukaemia Research Institute

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/josep-carreras-leukaemia-research-institute/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 54.4 |
| Citations | 152,819 |
| City | Barcelona |
| Country | ES |
| Description | Josep Carreras Leukaemia Research Institute is a research organisation in Barcelona, ES. OpenAlex records 2,878 works and 152,819 citations for it. 676 researchers list it as their most recent affiliation. |
| Homepage | http://www.carrerasresearch.org/en/ |
| OpenAlex ID | https://openalex.org/I4210089592 |
| Researchers | 676 |
| ROR ID | https://ror.org/00btzwk36 |
| Type | facility |
| Works | 2,878 |

## University papers

- [Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/idecabtagene-vicleucel-in-relapsed-and-refractory-multiple-myeloma/)
- [Teclistamab in Relapsed or Refractory Multiple Myeloma](https://scholariq.org/papers/teclistamab-in-relapsed-or-refractory-multiple-myeloma/)
- [Genetic Unmasking of an Epigenetically Silenced microRNA in Human Cancer Cells](https://scholariq.org/papers/genetic-unmasking-of-an-epigenetically-silenced-microrna-in-human-cancer-cells/)
- [Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma](https://scholariq.org/papers/lenalidomide-and-dexamethasone-in-transplant-ineligible-patients-with-myeloma/)
- [Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma](https://scholariq.org/papers/talquetamab-a-t-cell-redirecting-gprc5d-bispecific-antibody-for-multiple-myeloma/)
- [Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation](https://scholariq.org/papers/diagnosis-and-severity-criteria-for-sinusoidal-obstruction-syndrome-veno/)
- [Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study](https://scholariq.org/papers/teclistamab-a-b-cell-maturation-antigen-cd3-bispecific-antibody-in-patients-with/)
- [Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or/)

## University top topics

Showing 8 of 25.

- [Acute Myeloid Leukemia Research](https://scholariq.org/topics/acute-myeloid-leukemia-research/)
- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)
- [Epigenetics and DNA Methylation](https://scholariq.org/topics/epigenetics-and-dna-methylation/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Hematopoietic Stem Cell Transplantation](https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/)
- [Chronic Myeloid Leukemia Treatments](https://scholariq.org/topics/chronic-myeloid-leukemia-treatments/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.